Coloplast Shares Tumble After JPMorgan Downgrade on Valuation Concerns

Shares of Coloplast (CSE:COLOb) slid on Wednesday after JPMorgan downgraded the Danish medical device company, citing significant valuation concerns and uncertainty surrounding its future financial targets.

The stock fell 3.3% to trade at DKK 431.9, hitting an intraday low of DKK 427.8 during the session.

JPMorgan's Bearish Case

The sell-off was triggered by a new analyst note from JPMorgan, which lowered its rating on Coloplast to Underweight from a previous Neutral stance. The bank also slashed its December 2027 price target for the stock by approximately 22%, from DKK 484 to DKK 377.

In the note, analyst Anchal Verma argued that the stock's risk/reward balance is skewed to the downside. Key concerns highlighted by the bank include:

Ad

• Valuation Premium: Coloplast shares trade at a price-to-earnings ratio of 35.35, a roughly 20% premium to the broader medtech sector.
• Slowing Growth: This premium valuation exists despite the company's earnings growth running "well below sector peers," according to the report.
• Margin Pressure: Analysts pointed to soft margins reported in the company's fiscal third quarter as a drag on near-term sentiment.

Strategic Uncertainty Looms

JPMorgan's downgrade also crystallized investor concerns about the company's strategic direction. The bank expects Coloplast's new CEO may revisit and potentially lower the company's mid-term financial targets.

This guidance revision is anticipated to coincide with the presentation of full-year results on November 3. The report noted that this view was informed by management commentary during the last earnings update. The stock was already carrying elevated short interest before the downgrade, indicating that some market participants were positioned for a potential decline.